News

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types.
Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of ...
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and up to $7.6 billion in potential milestone payments through 2028. Disclaimer: This is an AI-generated summary of a press release ...
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types ; MAINZ, Germany, ...
Bristol Myers Squibb and BioNTech announced a strategic partnership June 2 to co-develop and co-commercialize BioNTech’s next-generation cancer immunotherapy – BNT327 – across numerous solid ...
MAINZ, Germany, and PRINCETON, USA, June 2, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into ...